Belgian 2024 guidance on the use of pre-exposure prophylaxis.

IF 1.6 4区 医学 Q2 Medicine Acta Clinica Belgica Pub Date : 2024-04-01 Epub Date: 2024-05-22 DOI:10.1080/17843286.2024.2356337
Jens T Van Praet, Sophie Henrard, Chris Kenyon, Agnès Libois, Annelies Meuwissen, Anne-Sophie Sauvage, Anne Vincent, Jef Vanhamel, Gert Scheerder
{"title":"Belgian 2024 guidance on the use of pre-exposure prophylaxis.","authors":"Jens T Van Praet, Sophie Henrard, Chris Kenyon, Agnès Libois, Annelies Meuwissen, Anne-Sophie Sauvage, Anne Vincent, Jef Vanhamel, Gert Scheerder","doi":"10.1080/17843286.2024.2356337","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to develop a guidance on the use of pre-exposure prophylaxis (PrEP) for HIV tailored to the Belgian context.</p><p><strong>Methods: </strong>Different aspects of PrEP care were judged by an expert group of nine Belgian clinicians, seeking consensus for areas of controversies.</p><p><strong>Results: </strong>PrEP should be considered in HIV negative patients at high risk of acquiring HIV. Currently, only oral tenofovir/emtricitabine is available in Belgium for PrEP, which can be used daily, or also event-driven in cisgender men and trans women who are not taking exogenous estradiol-based hormones. Personal counselling directed at medication adherence and sexual health should have a central role in PrEP care. At the initial assessment clinicians should give attention to symptoms of an acute HIV infection, the patients' immunization status and renal function. A regular follow-up must be set up to diagnose HIV seroconversion, treat sexually transmitted infections, and manage side effects of PrEP.</p><p><strong>Conclusion: </strong>The Belgian guidance on the use of PrEP provides a point of reference for standard PrEP care in Belgium and will be periodically updated.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2024.2356337","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: We aimed to develop a guidance on the use of pre-exposure prophylaxis (PrEP) for HIV tailored to the Belgian context.

Methods: Different aspects of PrEP care were judged by an expert group of nine Belgian clinicians, seeking consensus for areas of controversies.

Results: PrEP should be considered in HIV negative patients at high risk of acquiring HIV. Currently, only oral tenofovir/emtricitabine is available in Belgium for PrEP, which can be used daily, or also event-driven in cisgender men and trans women who are not taking exogenous estradiol-based hormones. Personal counselling directed at medication adherence and sexual health should have a central role in PrEP care. At the initial assessment clinicians should give attention to symptoms of an acute HIV infection, the patients' immunization status and renal function. A regular follow-up must be set up to diagnose HIV seroconversion, treat sexually transmitted infections, and manage side effects of PrEP.

Conclusion: The Belgian guidance on the use of PrEP provides a point of reference for standard PrEP care in Belgium and will be periodically updated.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
比利时 2024 年接触前预防使用指南。
目的我们的目的是根据比利时的国情,制定一份艾滋病暴露前预防(PrEP)指南:由九名比利时临床医生组成的专家组对 PrEP 治疗的不同方面进行了判断,并就存在争议的领域寻求共识:结果:HIV 阴性患者感染 HIV 的风险较高,应考虑 PrEP。目前,比利时只有口服替诺福韦/恩曲他滨可用于 PrEP,该药物可每天使用,也可在不服用外源性雌二醇激素的顺性男性和变性女性中按事件驱动使用。针对服药依从性和性健康的个人咨询应在 PrEP 治疗中发挥核心作用。在初步评估时,临床医生应关注急性 HIV 感染的症状、患者的免疫状况和肾功能。必须进行定期随访,以诊断艾滋病病毒血清转换、治疗性传播感染并控制 PrEP 的副作用:比利时 PrEP 使用指南为比利时的标准 PrEP 护理提供了一个参考点,并将定期更新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Clinica Belgica
Acta Clinica Belgica 医学-医学:内科
CiteScore
2.90
自引率
0.00%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
期刊最新文献
Flemish consensus statement on the prevention, diagnosis and treatment of urinary tract infections in older nursing home residents. Validation of EUCAST rapid antimicrobial susceptibility testing directly from positive blood cultures in a non-automated lab setting. A multimodal treatment of basilar artery re-occlusion - case report. 'Iatrogenic septic pit': empyema, a rare complication after endobronchial valve placement. The first reported familial case of statin-induced immune-mediated necrotizing myopathy associated with anti-hydroxy-3-methylglutaryl-CoA reductase autoantibodies and HLA DRB1*11:01
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1